{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T16:57:37Z","timestamp":1780333057326,"version":"3.54.1"},"reference-count":92,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Cystic fibrosis (CF) is a monogenic disease caused by mutations in the CF transmembrane conductance regulator (<jats:italic>CFTR<\/jats:italic>) gene. Premature termination codons (PTCs) represent \u223c9% of CF mutations that typically cause severe expression defects of the CFTR anion channel. Despite the prevalence of PTCs as the underlying cause of genetic diseases, understanding the therapeutic susceptibilities of their molecular defects, both at the transcript and protein levels remains partially elucidated. Given that the molecular pathologies depend on the PTC positions in CF, multiple pharmacological interventions are required to suppress the accelerated nonsense-mediated mRNA decay (NMD), to correct the CFTR conformational defect caused by misincorporated amino acids, and to enhance the inefficient stop codon readthrough. The G418-induced readthrough outcome was previously investigated only in reporter models that mimic the impact of the local sequence context on PTC mutations in CFTR. To identify the misincorporated amino acids and their ratios for PTCs in the context of full-length CFTR readthrough, we developed an affinity purification (AP)-tandem mass spectrometry (AP-MS\/MS) pipeline. We confirmed the incorporation of Cys, Arg, and Trp residues at the UGA stop codons of G542X, R1162X, and S1196X in CFTR. Notably, we observed that the Cys and Arg incorporation was favored over that of Trp into these CFTR PTCs, suggesting that the transcript sequence beyond the proximity of PTCs and\/or other factors can impact the amino acid incorporation and full-length CFTR functional expression. Additionally, establishing the misincorporated amino acid ratios in the readthrough CFTR PTCs aided in maximizing the functional rescue efficiency of PTCs by optimizing CFTR modulator combinations. Collectively, our findings contribute to the understanding of molecular defects underlying various CFTR nonsense mutations and provide a foundation to refine mutation-dependent therapeutic strategies for various CF-causing nonsense mutations.<\/jats:p>","DOI":"10.3389\/fphar.2024.1389586","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T04:44:20Z","timestamp":1714020260000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Readthrough-induced misincorporated amino acid ratios guide mutant-specific therapeutic approaches for two CFTR nonsense mutations"],"prefix":"10.3389","volume":"15","author":[{"given":"Aiswarya","family":"Premchandar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiji","family":"Ming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abed","family":"Baiad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dillon F.","family":"Da Fonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Faubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Veit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gergely L.","family":"Lukacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/s41586-023-06133-1","article-title":"Engineered tRNAs suppress nonsense mutations in cells and in vivo","volume":"618","author":"Albers","year":"2023","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41467-017-00444-4","article-title":"Chaperones rescue the energetic landscape of mutant CFTR at single molecule and in cell","volume":"8","author":"Bagdany","year":"2017","journal-title":"Nat. Commun."},{"key":"B3","doi-asserted-by":"publisher","first-page":"113413","DOI":"10.1016\/j.celrep.2023.113413","article-title":"Synonymous codon usage regulates translation initiation","volume":"42","author":"Barrington","year":"2023","journal-title":"Cell Rep."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/nm1197-1280","article-title":"Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line","volume":"3","author":"Bedwell","year":"1997","journal-title":"Nat. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1261\/rna.054452.115","article-title":"Rules of UGA-N decoding by near-cognate tRNAs and analysis of readthrough on short uORFs in yeast","volume":"22","author":"Beznoskova","year":"2016","journal-title":"RNA"},{"key":"B6","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3390\/jcm9020289","article-title":"Screening readthrough compounds to suppress nonsense mutations: possible application to \u03b2-thalassemia","volume":"9","author":"Borgatti","year":"2020","journal-title":"J. Clin. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.biochi.2014.10.027","article-title":"NMD: at the crossroads between translation termination and ribosome recycling","volume":"114","author":"Celik","year":"2015","journal-title":"Biochimie"},{"key":"B8","doi-asserted-by":"publisher","first-page":"L756","DOI":"10.1152\/ajplung.00038.2023","article-title":"The synthetic aminoglycoside ELX-02 induces readthrough of G550X-CFTR producing superfunctional protein that can be further enhanced by CFTR modulators","volume":"324","author":"Chen","year":"2023","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"ar38","DOI":"10.1091\/mbc.E21-08-0382","article-title":"Selective destabilization of polypeptides synthesized from NMD-targeted transcripts","volume":"32","author":"Chu","year":"2021","journal-title":"Mol. Biol. Cell"},{"key":"B10","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/humu.23692","article-title":"The effect of premature termination codon mutations on CFTR mRNA abundance in human nasal epithelium and intestinal organoids: a basis for read-through therapies in cystic fibrosis","volume":"40","author":"Clarke","year":"2019","journal-title":"Hum. Mutat."},{"key":"B11","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.jcf.2021.01.009","article-title":"Targeting G542X CFTR nonsense alleles with ELX-02 restores CFTR function in human-derived intestinal organoids","volume":"20","author":"Crawford","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"B12","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.jmb.2006.10.086","article-title":"Domain interdependence in the biosynthetic assembly of CFTR","volume":"365","author":"Cui","year":"2007","journal-title":"J. Mol. Biol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/nrg3849","article-title":"Cystic fibrosis genetics: from molecular understanding to clinical application","volume":"16","author":"Cutting","year":"2015","journal-title":"Nat. Rev. Genet."},{"key":"B14","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1080\/15476286.2015.1068497","article-title":"Translational readthrough potential of natural termination codons in eucaryotes--The impact of RNA sequence","volume":"12","author":"Dabrowski","year":"2015","journal-title":"RNA Biol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s10020-018-0024-7","article-title":"Advances in therapeutic use of a drug-stimulated translational readthrough of premature termination codons","volume":"24","author":"Dabrowski","year":"2018","journal-title":"Mol. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/S2213-2600(16)00023-0","article-title":"Progress in therapies for cystic fibrosis","volume":"4","author":"De Boeck","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.jcf.2021.09.020","article-title":"Functional restoration of CFTR nonsense mutations in intestinal organoids","volume":"21","author":"de Poel","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1091\/mbc.e08-09-0950","article-title":"Cooperative assembly and misfolding of CFTR domains in vivo","volume":"20","author":"Du","year":"2009","journal-title":"Mol. Biol. Cell"},{"key":"B19","doi-asserted-by":"publisher","first-page":"36639","DOI":"10.1074\/jbc.M112.393637","article-title":"Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner","volume":"287","author":"Eckford","year":"2012","journal-title":"J. Biol. Chem."},{"key":"B20","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00441-005-0062-7","article-title":"Towards an in vitro model of cystic fibrosis small airway epithelium: characterisation of the human bronchial epithelial cell line CFBE41o","volume":"323","author":"Ehrhardt","year":"2006","journal-title":"Cell Tissue Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1093\/hmg\/8.10.1893","article-title":"Nonsense-mediated mRNA decay in health and disease","volume":"8","author":"Frischmeyer","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/S0140-6736(23)01608-2","article-title":"The future of cystic fibrosis treatment: from disease mechanisms to novel therapeutic approaches","volume":"402","author":"Graeber","year":"2023","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jcf.2022.01.009","article-title":"Worldwide rates of diagnosis and effective treatment for cystic fibrosis","volume":"21","author":"Guo","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"B24","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1074\/jbc.M116.764720","article-title":"Correctors and potentiators rescue function of the truncated W1282x-cystic fibrosis transmembrane regulator (CFTR) translation product","volume":"292","author":"Haggie","year":"2017","journal-title":"J. Biol. Chem."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"B26","doi-asserted-by":"publisher","first-page":"4404","DOI":"10.1073\/pnas.1215982110","article-title":"Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle","volume":"110","author":"Jih","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1101\/gr.119974.110","article-title":"Evidence of abundant stop codon readthrough in Drosophila and other metazoa","volume":"21","author":"Jungreis","year":"2011","journal-title":"Genome Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"E6731-E6740","DOI":"10.1073\/pnas.1721431115","article-title":"Decoding on the ribosome depends on the structure of the mRNA phosphodiester backbone","volume":"115","author":"Keedy","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B29","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/wrna.95","article-title":"Suppression of nonsense mutations as a therapeutic approach to treat genetic diseases","volume":"2","author":"Keeling","year":"2011","journal-title":"Wiley Interdiscip. Rev. RNA"},{"key":"B30","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.ejmg.2006.04.003","article-title":"Translational readthrough induction of pathogenic nonsense mutations","volume":"49","author":"Kellermayer","year":"2006","journal-title":"Eur. J. Med. Genet."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1080\/13543784.2020.1828862","article-title":"ELX-02: an investigational read-through agent for the treatment of nonsense mutation-related genetic disease","volume":"29","author":"Kerem","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1038\/s41467-022-30668-y","article-title":"Gene-specific nonsense-mediated mRNA decay targeting for cystic fibrosis therapy","volume":"13","author":"Kim","year":"2022","journal-title":"Nat. Commun."},{"key":"B33","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1261\/rna.070136.118","article-title":"UPFront and center in RNA decay: UPF1 in nonsense-mediated mRNA decay and beyond","volume":"25","author":"Kim","year":"2019","journal-title":"RNA"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e2000779","DOI":"10.1371\/journal.pbio.2000779","article-title":"Alteration of protein function by a silent polymorphism linked to tRNA abundance","volume":"15","author":"Kirchner","year":"2017","journal-title":"PLoS Biol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.omtn.2022.04.033","article-title":"Efficient suppression of endogenous CFTR nonsense mutations using anticodon-engineered transfer RNAs","volume":"28","author":"Ko","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B36","doi-asserted-by":"publisher","first-page":"8051","DOI":"10.1038\/s41467-023-43904-w","article-title":"Shuttle peptide delivers base editor RNPs to rhesus monkey airway epithelial cells in vivo","volume":"14","author":"Kulhankova","year":"2023","journal-title":"Nat. Commun."},{"key":"B37","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.jcf.2019.12.001","article-title":"Functional rescue of c.3846G>A (W1282X) in patient-derived nasal cultures achieved by inhibition of nonsense mediated decay and protein modulators with complementary mechanisms of action","volume":"19","author":"Laselva","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e154571","DOI":"10.1172\/JCI154571","article-title":"Small-molecule eRF3a degraders rescue CFTR nonsense mutations by promoting premature termination codon readthrough","volume":"132","author":"Lee","year":"2022","journal-title":"J. Clin. Invest."},{"key":"B39","doi-asserted-by":"publisher","first-page":"175","DOI":"10.5483\/bmbrep.2017.50.4.015","article-title":"Nonsense-mediated mRNA decay at the crossroads of many cellular pathways","volume":"50","author":"Lejeune","year":"2017","journal-title":"BMB Rep."},{"key":"B40","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1002\/cpdd.914","article-title":"A randomized, double-blind, placebo-controlled, multiple dose escalation study to evaluate the safety and pharmacokinetics of ELX-02 in healthy subjects","volume":"10","author":"Leubitz","year":"2021","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1038\/sj.ejhg.5201889","article-title":"The efficiency of nonsense-mediated mRNA decay is an inherent character and varies among different cells","volume":"15","author":"Linde","year":"","journal-title":"Eur. J. Hum. Genet."},{"key":"B42","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1172\/JCI28523","article-title":"Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin","volume":"117","author":"Linde","year":"","journal-title":"J. Clin. Invest."},{"key":"B43","doi-asserted-by":"publisher","first-page":"4019","DOI":"10.1073\/pnas.1311750111","article-title":"Hydroxylation of the eukaryotic ribosomal decoding center affects translational accuracy","volume":"111","author":"Loenarz","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B44","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1080\/17460441.2021.1912732","article-title":"Discovery of CFTR modulators for the treatment of cystic fibrosis","volume":"16","author":"Lopes-Pacheco","year":"2021","journal-title":"Expert Opin. Drug Discov."},{"key":"B45","doi-asserted-by":"publisher","first-page":"8928","DOI":"10.1093\/nar\/gku608","article-title":"Evidence of efficient stop codon readthrough in four mammalian genes","volume":"42","author":"Loughran","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"B46","doi-asserted-by":"publisher","first-page":"e1009538","DOI":"10.1371\/journal.pgen.1009538","article-title":"Transcriptome-wide investigation of stop codon readthrough in Saccharomyces cerevisiae","volume":"17","author":"Mangkalaphiban","year":"2021","journal-title":"PLoS Genet."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1017\/s1355838200000716","article-title":"Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system","volume":"6","author":"Manuvakhova","year":"2000","journal-title":"RNA"},{"key":"B48","doi-asserted-by":"publisher","first-page":"4813","DOI":"10.1093\/nar\/gku159","article-title":"Deciphering the rules by which dynamics of mRNA secondary structure affect translation efficiency in Saccharomyces cerevisiae","volume":"42","author":"Mao","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.omtm.2021.02.020","article-title":"Increased CFTR expression and function from an optimized lentiviral vector for cystic fibrosis gene therapy","volume":"21","author":"Marquez Loza","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B50","doi-asserted-by":"publisher","first-page":"508","DOI":"10.3324\/haematol.2018.212118","article-title":"Variable readthrough responsiveness of nonsense mutations in hemophilia A","volume":"105","author":"Martorell","year":"2020","journal-title":"Haematologica"},{"key":"B51","doi-asserted-by":"publisher","first-page":"5431","DOI":"10.1073\/pnas.92.12.5431","article-title":"Translational termination efficiency in mammals is influenced by the base following the stop codon","volume":"92","author":"McCaughan","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"17117","DOI":"10.1038\/nmicrobiol.2017.117","article-title":"Translational fidelity and mistranslation in the cellular response to stress","volume":"2","author":"Mohler","year":"2017","journal-title":"Nat. Microbiol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/humu.20763","article-title":"A meta-analysis of nonsense mutations causing human genetic disease","volume":"29","author":"Mort","year":"2008","journal-title":"Hum. Mutat."},{"key":"B55","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s40259-016-0157-6","article-title":"Targeting nonsense mutations in diseases with translational read-through-inducing drugs (TRIDs)","volume":"30","author":"Nagel-Wolfrum","year":"2016","journal-title":"BioDrugs"},{"key":"B56","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/s0968-0004(98)01208-0","article-title":"A rule for termination-codon position within intron-containing genes: when nonsense affects RNA abundance","volume":"23","author":"Nagy","year":"1998","journal-title":"Trends Biochem. Sci."},{"key":"B57","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.devcel.2018.02.001","article-title":"Chaperone-independent peripheral quality control of CFTR by RFFL E3 ligase","volume":"44","author":"Okiyoneda","year":"2018","journal-title":"Dev. Cell"},{"key":"B58","doi-asserted-by":"publisher","first-page":"17640","DOI":"10.1038\/s41598-019-54158-2","article-title":"Nanomolar-potency 'co-potentiator' therapy for cystic fibrosis caused by a defined subset of minimal function CFTR mutants","volume":"9","author":"Phuan","year":"2019","journal-title":"Sci. Rep."},{"key":"B59","doi-asserted-by":"publisher","first-page":"4104","DOI":"10.1038\/s41467-020-17879-x","article-title":"Quantitative tRNA-sequencing uncovers metazoan tissue-specific tRNA regulation","volume":"11","author":"Pinkard","year":"2020","journal-title":"Nat. Commun."},{"key":"B60","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1186\/s12864-019-5864-1","article-title":"Assessing cell-specific effects of genetic variations using tRNA microarrays","volume":"20","author":"Polte","year":"2019","journal-title":"BMC Genomics"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00080-2017","article-title":"Factors influencing readthrough therapy for frequent cystic fibrosis premature termination codons","volume":"4","author":"Pranke","year":"2018","journal-title":"ERJ Open Res."},{"key":"B62","doi-asserted-by":"publisher","first-page":"7375","DOI":"10.1038\/s41598-017-07504-1","article-title":"Correction of CFTR function in nasal epithelial cells from cystic fibrosis patients predicts improvement of respiratory function by CFTR modulators","volume":"7","author":"Pranke","year":"2017","journal-title":"Sci. Rep."},{"key":"B63","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.jcf.2022.10.010","article-title":"The U UGA C sequence provides a favorable context to ELX-02 induced CFTR readthrough","volume":"22","author":"Pranke","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s00109-011-0787-6","article-title":"Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54","volume":"89","author":"Rowe","year":"2011","journal-title":"J. Mol. Med. Berl."},{"key":"B65","doi-asserted-by":"publisher","first-page":"12508","DOI":"10.1073\/pnas.1605336113","article-title":"Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppression","volume":"113","author":"Roy","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B66","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1073\/pnas.1424127112","article-title":"Nonsense suppression by near-cognate tRNAs employs alternative base pairing at codon positions 1 and 3","volume":"112","author":"Roy","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B67","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1021\/acsmedchemlett.6b00006","article-title":"Design of novel aminoglycoside derivatives with enhanced suppression of diseases-causing nonsense mutations","volume":"7","author":"Sabbavarapu","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"B68","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1261\/rna.079797.123","article-title":"Posttranscriptional modification to the core of tRNAs modulates translational misreading errors","volume":"30","author":"Saleh","year":"2023","journal-title":"RNA"},{"key":"B69","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1038\/s41467-022-29935-9","article-title":"CFTR mRNAs with nonsense codons are degraded by the SMG6-mediated endonucleolytic decay pathway","volume":"13","author":"Sanderlin","year":"2022","journal-title":"Nat. Commun."},{"key":"B70","doi-asserted-by":"publisher","first-page":"12706","DOI":"10.1038\/s41598-019-48971-y","article-title":"Phosphorylation-dependent modulation of CFTR macromolecular signalling complex activity by cigarette smoke condensate in airway epithelia","volume":"9","author":"Schnur","year":"2019","journal-title":"Sci. Rep."},{"key":"B71","doi-asserted-by":"publisher","first-page":"e1006196","DOI":"10.1371\/journal.pgen.1006196","article-title":"Functional translational readthrough: a systems biology perspective","volume":"12","author":"Schueren","year":"2016","journal-title":"PLoS Genet."},{"key":"B72","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1083\/jcb.200312018","article-title":"Misfolding diverts CFTR from recycling to degradation: quality control at early endosomes","volume":"164","author":"Sharma","year":"2004","journal-title":"J. Cell Biol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"e1007723","DOI":"10.1371\/journal.pgen.1007723","article-title":"Capitalizing on the heterogeneous effects of CFTR nonsense and frameshift variants to inform therapeutic strategy for cystic fibrosis","volume":"14","author":"Sharma","year":"2018","journal-title":"PLoS Genet."},{"key":"B74","doi-asserted-by":"publisher","first-page":"6868","DOI":"10.1038\/s41467-023-42586-8","article-title":"Folding correctors can restore CFTR posttranslational folding landscape by allosteric domain-domain coupling","volume":"14","author":"Soya","year":"2023","journal-title":"Nat. Commun."},{"key":"B75","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1097\/MCP.0000000000001019","article-title":"Genetic therapies in cystic fibrosis","volume":"29","author":"Taylor-Cousar","year":"2023","journal-title":"Curr. Opin. Pulm. Med."},{"key":"B76","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del","volume":"377","author":"Taylor-Cousar","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B77","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1093\/nar\/gkh201","article-title":"The major 5' determinant in stop codon read-through involves two adjacent adenines","volume":"32","author":"Tork","year":"2004","journal-title":"Nucleic Acids Res."},{"key":"B78","doi-asserted-by":"publisher","first-page":"e202101217","DOI":"10.26508\/lsa.202101217","article-title":"Nonsense-mediated mRNA decay uses complementary mechanisms to suppress mRNA and protein accumulation","volume":"5","author":"Udy","year":"2022","journal-title":"Life Sci. Alliance"},{"key":"B79","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.jcf.2018.12.001","article-title":"Isogenic cell models of cystic fibrosis-causing variants in natively expressing pulmonary epithelial cells","volume":"18","author":"Valley","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"B80","doi-asserted-by":"publisher","first-page":"18825","DOI":"10.1073\/pnas.0904709106","article-title":"Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770","volume":"106","author":"Van Goor","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B81","doi-asserted-by":"publisher","first-page":"18843","DOI":"10.1073\/pnas.1105787108","article-title":"Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809","volume":"108","author":"Van Goor","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B82","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1091\/mbc.E14-04-0935","article-title":"From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations","volume":"27","author":"Veit","year":"2016","journal-title":"Mol. Biol. Cell"},{"key":"B83","doi-asserted-by":"publisher","first-page":"4188","DOI":"10.1091\/mbc.E12-06-0424","article-title":"Proinflammatory cytokine secretion is suppressed by TMEM16A or CFTR channel activity in human cystic fibrosis bronchial epithelia","volume":"23","author":"Veit","year":"2012","journal-title":"Mol. Biol. Cell"},{"key":"B84","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.jcf.2019.10.011","article-title":"Mutation-specific dual potentiators maximize rescue of CFTR gating mutants","volume":"19","author":"Veit","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"B85","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.jcf.2021.03.011","article-title":"Elexacaftor co-potentiates the activity of F508del and gating mutants of CFTR","volume":"20","author":"Veit","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1038\/s41591-018-0200-x","article-title":"Structure-guided combination therapy to potently improve the function of mutant CFTRs","volume":"24","author":"Veit","year":"2018","journal-title":"Nat. Med."},{"key":"B87","doi-asserted-by":"publisher","first-page":"11972","DOI":"10.3390\/ijms222111972","article-title":"Comprehensive analysis of combinatorial pharmacological treatments to correct nonsense mutations in the CFTR gene","volume":"22","author":"Venturini","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B88","doi-asserted-by":"publisher","first-page":"101140","DOI":"10.1016\/j.omtm.2023.101140","article-title":"Molecular and functional correction of a deep intronic splicing mutation in CFTR by CRISPR-Cas9 gene editing","volume":"31","author":"Walker","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B89","doi-asserted-by":"publisher","first-page":"e52611","DOI":"10.7554\/eLife.52611","article-title":"Stop codon context influences genome-wide stimulation of termination codon readthrough by aminoglycosides","volume":"9","author":"Wangen","year":"2020","journal-title":"Elife"},{"key":"B90","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.1093\/hmg\/ddx196","article-title":"Identification of the amino acids inserted during suppression of CFTR nonsense mutations and determination of their functional consequences","volume":"26","author":"Xue","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"B91","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1113\/JP278418","article-title":"Positional effects of premature termination codons on the biochemical and biophysical properties of CFTR","volume":"598","author":"Yeh","year":"2020","journal-title":"J. Physiol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.tig.2020.08.010","article-title":"The branched nature of the nonsense-mediated mRNA decay pathway","volume":"37","author":"Yi","year":"2021","journal-title":"Trends Genet."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1389586\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T04:44:24Z","timestamp":1714020264000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1389586\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,25]]},"references-count":92,"alternative-id":["10.3389\/fphar.2024.1389586"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1389586","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,25]]},"article-number":"1389586"}}